ETFMG Treatments, Testing and Advancements ETF (GERM)
| 28.43 Delayed Data As of Oct 23 |  -0.06 / -0.21%Today’s Change | 23.80 Today|||52-Week Range 35.15 | -- Year-to-Date |
Investment Objective
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the Prime Treatments, Testing and Advancements Index. The fund invests at least 80% of its total assets in the component securities of the index. The index tracks the performance of U.S.-listed equity securities or depositary receipts of companies that (i) perform research, development, and commercialization of treatments or vaccines for infectious diseases or (ii) engage in the research, development, manufacturing, and provision of biological tests for patients. The fund is non-diversified.
Latest GERM News
| Coronavirus-Themed ETFs in Focus as the Pandemic Worsens Oct 23 / Zacks.com - Paid Partner Content | Moderna Expects COVID-19 Vaccine Data in November: ETFs to Gain Oct 22 / Zacks.com - Paid Partner Content |
Performance
| 1 month | +5.88% | 3 years | -- | |
| 3 months | -12.70% | 5 years | -- | |
| 1 year | -- | Since inception | +14.18% |
Data through 10/24/2020
Quote Details
| Previous close | $28.49 |
| Open day’s range | 28.43 – 28.43 |
| Net asset value (NAV) | 28.54 (10/23/2020) |
| Daily volume | 16,078 |
| Average volume (3 months) | 1,537 |
Data as of 4:00pm ET, 10/23/2020
Peer Comparisonvs. Health ETFs
| GERM | Category | |
|---|---|---|
| Performance 5-yr return | -- | +10.93% |
| Expense Gross exp ratio | 0.68% | 1.22% |
| Risk 5 year sharpe ratio | -- | 0.59 |
| Net assets | $54.0M | $3.5B |
| Average market cap | $6.7B | $40.5B |
| Average P/E | -- | 29.8 |
| Dividend / Share | -- | 0.27% |
Competitors
| No competitors data available. |
Holdings
Top 5 SectorsPortfolio weighting
| Business service | -- |
| Consumer goods | -- |
| Consumer service | -- |
| Energy | -- |
| Financial service | -- |
Top 10 HoldingsPortfolio weighting
| MRNA Moderna Inc | 6.48% |
| BNTX BioNTech SE | 5.97% |
| DGX Quest Diagnostics Inc | 5.47% |
| LH Laboratory Corporation of America Holdings | 5.47% |
| BIO Bio Rad Laboratories Inc | 5.41% |
| QDEL Quidel Corp | 5.08% |
| ADPT Adaptive Biotechnologies Corp | 4.37% |
| VIR Vir Biotechnology Inc | 4.27% |
| ALNY Alnylam Pharmaceuticals Inc | 4.21% |
| NVAX Novavax Inc | 4.08% |
